Financial Snapshot
Revenues
Revenues
Revenue YoY Change
Revenues
Expenses
Cost Of Revenues
Gross Profit
Gross Profit Margin
Gross Profit
Selling, General & Admin Expense
Research & Development
Depreciation, Depletion & Amortization
SGA Expense to Gross Profit Ratio
R&D To Gross Profit Ratio
DDA To Gross Profit Ratio
Operating Expenses Total
Operating Profits/Loss
Operational Expenses
Interest Expenses
Interest Expenses To Operating Income %
Other Expense/Income
Interest & Other Expense/Income
Income/Loss
Pretax Income
Income Tax
Net Profits/Loss
Pretax Income YoY Change
Income Tax Rate
Net Profits/Loss YoY Change
Basic EPS
Net Income To Revenue Ratio
Pretax & Net Income
Assets & Liabilities
Cash & Short-Term Investments
Cash & Equivalents
Cash To Operating Expenses Ratio
Inventory
Receivables
Total Short-Term Assets
Property, Plant And Equipment
Long-Term Investments
Total Long-Term Assets
Total Assets
Net Income To Total Assets Percentage
Accounts Payable
Short-Term Debt
Long Term Debt Due
Total Short-Term Liabilities
Long-Term Debt
Other Long-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
Short-Term To Long-Term Debt Ratio
Short-Term Assets To Debt Ratio
Long-Term Debt To Net Income Ratio
Assets & Liabilities
Ownership
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares
Stock Issuance & Repurchase
Ownership Data
Return On Shareholders' Equity
Book Value
Free Cash Flow
Free Cash Flow YoY
Dividends
Dividends
Stock Price
About Morphic Holding, Inc.
Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2019-06-27. The firm is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The firm is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). The company has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
Industry: Pharmaceutical Preparations Peers: Avidity Biosciences Inc Cogent Biosciences Inc Crinetics Pharmaceuticals Inc Emergent BioSolutions Inc Enanta Pharmaceuticals Inc Erasca Inc Forma Therapeutics Holdings, Inc. ImmunoGen, Inc. Regenxbio Inc
